European Primary Care Cardiovascular Society

Weight loss induction by GLP-1RA in adults with overweight or obesity

10' education - Mar. 25, 2021 - Prof. Robert Kushner, MD

High incidence of thrombotic complications in first and second COVID-19 wave

5' education - Mar. 5, 2021 - Fleur Kaptein, MD

The future of CV medicine: anti-inflammation

10' education - Mar. 5, 2021 - Prof. Paul Ridker, MD

Treat also older adults to lower LDL-c

5' education - Jan. 19, 2021 - Prof. Børge Nordestgaard, MD

Majority side effects of statins also present with placebo

3' education - Dec. 3, 2020 - Prof. Darrel Francis, MD

Widespread atherosclerosis in Swedish population

3' education - Dec. 3, 2020 - Prof. Göran Bergström, MD, PhD

Potentially no contradiction between omega-3 fatty acids trials

3' education - Dec. 3, 2020 - Prof. Deepak Bhatt, MD

The therapeutic options in HFrEF patients

3' education - Dec. 3, 2020 - Prof. Marc Pfeffer, MD, PhD

Omega-3 carboxylic acid has no effect on MACE in high risk patients

3' education - Dec. 3, 2020 - Prof. Michael Lincoff, MD

A polypill with or without aspirin to reduce global CVD burden

3' education - Dec. 3, 2020 - Prof. Salim Yusuf, MD

Reduced HF hospitalization in patients with iron deficiency after acute HF treated with ferric carboxymaltose

5' education - Dec. 3, 2020 - Prof. Piotr Ponikowski, MD, PhD

An update on COVID-19 at the AHA Scientific Sessions

10' education - Dec. 3, 2020 - Anthony Fauci, MD

2019 ESC guidelines on diabetes, pre-diabetes and CVD

10' education - Dec. 2, 2020 - Prof. Francesco Cosentino, MD

CVD prevention with GLP-1 receptor agonists

10' education - Nov. 10, 2020 - Prof. Kamlesh Khunti, MD

To achieve lower LDL-c goals, combination therapy is necessary

3' education - Oct. 28, 2020 - Prof. Kausik Ray, MD

Reducing CV risk in diabetes in primary care

10' education - Oct. 27, 2020 - Prof. Richard Hobbs, MD

Primary outcome reduced by anti-inflammatory drug in chronic coronary disease

3' education - Sep. 30, 2020 - Mark Nidorf, MD

Temporarily suspending or continuing ACEi/ARBs in hospitalized patients with COVID-19

3' education - Sep. 30, 2020 - Prof. Renato D. Lopes, MD, PhD

Consideration of BP lowering irrespective of prior CVD or baseline SBP

3' education - Sep. 30, 2020 - Kazem Rahimi, MD

Changes in the 2020 AF guidelines

3' education - Sep. 30, 2020 - Prof. Isabelle van Gelder, MD

Some cases after COVID-19 vaccination show clinical resemblance of heparin-induced thrombocytopenia

Literature - Apr. 6, 2021 - Greinacher A et al. - Research Square 2021 (NOT PEER-REVIEWED)

Some cases of thrombotic events combined with thrombocytopenia have been described after COVID-19 vaccination with AZD1222. This thrombotic disorder clinically resembles heparin-induced thrombocytopenia, with a different serological profile.

Objectively measured poor sleep efficiency associated with major adverse CV events

Literature - Mar. 26, 2021 - Yan B et al. - J Am Heart Assoc. 2021

This analysis of the Sleep Heart Health Study showed that objective sleep efficiency, measured by polysomnography, was associated with risk of major adverse CV events and CVD mortality.

Weight loss induction by GLP-1RA in adults with overweight or obesity

10' education - Mar. 25, 2021 - Prof. Robert Kushner, MD
Prof. Kushner discusses the details of the STEP 1 trial, in which treatment with semaglutide was compared to placebo for the outcome of weight loss in adults with overweight or obesity without T2DM.

Prof. Kushner discusses the details of the STEP 1 trial, in which treatment with semaglutide was compared to placebo for the outcome of weight loss in adults with overweight or obesity without T2DM.

No effect of statin on muscle symptoms compared to placebo in n-of-1 trials

Literature - Mar. 23, 2021 - Herrett E, et al. - BMJ 2021

This analysis of n-of-1 trials showed no effect of atorvastatin on muscle symptoms compared to placebo in people who had previously reported muscle symptoms on statins.

Almost linear association between sodium intake and BP in persons with and without hypertension

Literature - Mar. 16, 2021 - Filippini T, et al. - Circulation. 2021

Sodium intake was almost linearly associated with SBP and DBP, without a threshold for low or high sodium exposure. The effect of sodium reduction on BP was more pronounced in individuals with hypertension.

Long-term joint exposure to various ambient air pollutants associated with increased risk of incident HF

Literature - Mar. 15, 2021 - Wang M et al. - Eur Heart J. 2021

This study introduced an air pollution score to investigate the association between long-term joint exposure to various ambient air pollutants and risk of incident HF in the UK Biobank.

Elevated Lp(a) associated with increased CAD risk in individuals without a family history of CVD

Literature - Mar. 8, 2021 - Finneran P et al. - J Am Heart Assoc. 2021

This study investigated the risk of incident CAD in participants from the UK Biobank with and without a family history of CVD in a sibling or parent.

Increased CVD risk associated with lower SBP range in women compared to men

Literature - Mar. 5, 2021 - Ji H et al. - Circulation. 2021.

This study used data from four community-based cohort studies and investigated the relation between SBP and incident CVD. Increasing CVD risk was observed beginning at lower SBP thresholds in women than in men.

Once-weekly GLP1-RA results in sustained body weight loss in adults with overweight or obesity

Literature - Mar. 5, 2021 - Wilding JPH, et al. - N Engl J Med. 2021

The STEP 1 trial demonstrated a 15.3 kg weight loss and a sustained ≥5% reduction in body weight in 86.4% of participants after 68 weeks in individuals with overweight or obesity who were treated with semaglutide once-weekly.

High incidence of thrombotic complications in first and second COVID-19 wave

5' education - Mar. 5, 2021 - Fleur Kaptein, MD
Incidence of thrombotic complications remained high in hospitalized COVID-19 patients in the second wave. Thromboprophylaxis is therefore warranted in these patients.

Incidence of thrombotic complications remained high in hospitalized COVID-19 patients in the second wave. Thromboprophylaxis is therefore warranted in these patients.

Incidence of thrombotic complications in hospitalized COVID-19 patients remained high in second wave

Literature - Mar. 5, 2021 - Kaptein FHJ et al., - Thrombosis Research 2020.

Risk of overall mortality in COVID-19 patients was lower in the second wave, compared with the first wave. However, cumulative incidences of thrombotic complications remained high in the second wave.

The future of CV medicine: anti-inflammation

10' education - Mar. 5, 2021 - Prof. Paul Ridker, MD
From CANTOS to COLCOT to COPS to LoDoCo2: What are the lessons from these trials with anti-inflammatory treatment, in particular those with colchicine, in patients with residual inflammatory risk?

From CANTOS to COLCOT to COPS to LoDoCo2: What are the lessons from these trials with anti-inflammatory treatment, in particular those with colchicine, in patients with residual inflammatory risk?

Agenda